Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells

Molecular Endocrinology

Volumn 17, Issue 1, 2003, Pages 128-140

  Rivera, Omar J ^a   Song, Chung S ^a,b   Centonze, Victoria E ^a   Lechleiter, James D ^a   Chatterjee, Bandana ^a,b   Roy, Arun K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIBODY; BICALUTAMIDE; MARKER; STEROID HORMONE; STEROID RECEPTOR COACTIVATOR 1; YELLOW FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL AGING; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE; GENETIC TRANSFECTION; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR TRANSPORT; JELLYFISH; LASER MICROSCOPY; MALE; MONKEY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN LOCALIZATION; RECEPTOR BINDING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIGENS, NUCLEAR; AUTOANTIGENS; CELL NUCLEUS; COS CELLS; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HISTONE ACETYLTRANSFERASES; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 12244286062     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0165     Document Type: Article

References (46)

1. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, Bi BY, Chatterjee B 1999 Regulation of androgen action. Vitam Horm 55:309-352
2. Kokontis JM, Liao S 1999 Molecular action of androgen in the normal and neoplastic prostate. Vitam Horm 55:219-307
3. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
4. Wilson JD 2001 Androgens, androgen receptors, and male gender role behavior. Horm Behav 40:358-366
5. Jenster G, Trapman J, Brinkmann AO 1993 Nuclear import of the human androgen receptor. Biochem J 293:761-768
6. Tyagi, RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK 2000 Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 14:1162-1174
7. Tomura A, Goto K, Morinaga H, Nomura M, Okabe T, Yanase T, Takayanagi R, Nawata H 2001 The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. J Biol Chem 276:28395-28401
8. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175-200
9. Tan, JA, Hall SH, Hamil KG, Grossman G, Petrusz P, French FS 2002 Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators. J Biol Chem 277:16993-17001
10. Lin HK, Yeh S, Kang HY, Chang C 2001 Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-7205
11. Poukka H, Karvonen U, Janne OA, Palvimo JJ 2000 Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 97:14145-14150
12. McKenna NJ, Lanz RB, O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344
13. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2001 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nat Cell Biol 3:15-23
14. van Roessel P, Brand AH 2002 Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins. Nat Cell Biol 4:E15-E20
15. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, Juhlin L, Degos L, Calvo F, de The H 1995 The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10:1315-1324
16. Hodges M, Tissot C, Howe K, Grimwade D, Freemont PS 1998 Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am J Hum Genet 63:297-304
17. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss III JF, Maul GG 1999 PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147:221-234
18. Grobelny JV, Godwin AK, Broccoli D 2000 ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci 113:4577-4585
19. Wu G, Lee WH, Chen PL 2000 NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem 275:30618-30622
20. Kentsis A, Gordon RE, Borden KL 2002 From the cover: self-assembly properties of a model RING domain. Proc Natl Acad Sci USA 99:667-672
21. Baumann CT, Ma H, Wolford R, Reyes JC, Maruvada P, Lim C, Yen PM, Stallcup MR, Hager GL 2001 The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol Endocrinol 15:485-500
22. Salomoni P, Pandolfi PP 2002 The role of PML in tumor suppression. Cell 108:165-170
23. Muller S, Matunis MJ, Dejean A 1998 Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17:61-70
24. Szostecki C, Krippner H, Penner E, and Bautz FA 1987 Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). Clin Exp Immunol 68:108-116
25. Le XF, Vallian S, Mu ZM, Hung MC, Chang KS 1998 Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene 16:1839-1849
26. Muratani M, Gerlich D, Janicki SM, Gebhard M, Eils R, Spector DL 2002 Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat Cell Biol 4:106-110
27. Zhang J, Lazar MA 2000 The mechanism of action of thyroid hormones. Annu Rev Physiol 62:439-466
28. Llopis J, Westin S, Ricote M, Wang Z, Cho CY, Kurokawa R, Mullen TM, Rose DW, Rosenfeld MG, Tsien RY, Glass CK, Wang J 2000 Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. Proc Natl Acad Sci USA 97:4363-4368
29. Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, Pelicci PG 1998 Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16:2905-2913
30. Zhong S, Salomoni P, Pandolfi PP 2000 The transcriptional role of PML and the nuclear body. Nat Cell Biol 2:E85-E90
31. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP 1998 PML is essential for multiple apoptotic pathways. Nat Genet 20:266-272
32. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW 2000 PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14:2015-2027
33. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG 2000 PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406:207-210
34. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H 1998 PML induces a novel caspase-independent death process. Nat Genet 20:259-265
35. Doucas V, Tini M, Egan DA, Evans RM 1999 Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc Natl Acad Sci USA 96:2627-2632
36. Boisvert FM, Kruhlak MJ, Box AK, Hendzel MJ, Bazett-Jones DP 2001 The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. J Cell Biol 152:1099-1106
37. Stenoien DL, Mancini MG, Patel K, Allegretto EA, Smith CL, Mancini MA 2000 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Mol Endocrinol 14:518-534
38. Schaufele F, Chang CY, Liu W, Baxter JD, Nordeen SK, Wan Y, Day RN, McDonnell DP 2000 Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor. Mol Endocrinol 14:2024-2039
39. Saitoh M, Takayanagi R, Goto K, Fukamizu A, Tomura A, Yanase T, Nawata H 2002 The presence of both the amino-and carboxyl-terminal domains in the AR is essential for the completion of a transcriptionally active form with coactivators and intranuclear compartmentalization common to the steroid hormone receptors: a three-dimensional imaging study. Mol Endocrinol 16:694-706
40. Jackson PK 2001 A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15:3053-3058
41. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R 2001 PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15:3088-3103
42. Gross M, Liu B, Tan J, French FS, Carey M, Shuai K 2001 Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20:3880-3887
43. Kotaja N, Karvonen U, Janne OA, Palvimo JJ 2002 The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283-30288
44. Kotaja N, Karvonen U, Janne OA, Palvimo JJ 2002 PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol Cell Biol 22:5222-5234
45. Nickerson JA, Blencowe BJ, Penman S 1995 The architectural organization of nuclear metabolism. Int Rev Cytol 162A:67-123
46. Pederson, T 2000 Half a century of "the nuclear matrix." Mol Biol Cell 11:799-805